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AbstrAct
Objective The present study tested the hypothesis 
that arterial stiffness will be elevated across overall 
and specific inflammatory disorders compared with an 
inflammation-free comparison group.
Methods Adults (n=171 125) aged 40–70 years from 
the UK Biobank who were cardiovascular disease (CVD) 
free and who had their arterial stiffness assessed at 
the time of study recruitment between 2006 and 2010 
were included. The main exposure was represented by 
a global measure of chronic inflammatory disorders. 
Two inflammatory biomarker measures (eg, leucocytes 
count, granulocytes count) were included as markers 
of inflammation severity. The arterial stiffness index 
assessed by a non-invasive technique represented the 
study primary outcome measure.
results A total of 5976 (3%) participants diagnosed 
with inflammatory disorders and 165 149 participants 
without an inflammatory disorder had data on arterial 
stiffness. Adjusted linear regression analyses revealed 
a 14% increment in mean arterial stiffness for chronic 
inflammatory disorders (beta coefficient (β) 1.14, 95% 
CI 1.05 to 1.24, P=0.002) compared with no chronic 
inflammatory disorder. Arterial stiffness tended to 
increase (P value=0.031) with tertiles of leucocytes and 
granulocytes count. For instance, mean arterial stiffness 
values increased from 1.11 (95% CI 0.96 to 1.29) in 
the first tertile to 1.17 (95% CI 1.02 to 1.34) in the 
second tertile, and 1.21 (95% CI 1.05 to 1.39) in the 
third tertile of leucocytes count. There was evidence for 
similar associations with some of the most common 
individual inflammatory disorders, including psoriasis and 
rheumatoid arthritis.
conclusion Arterial stiffness was associated with 
multiple chronic inflammatory disorders. An increasing 
trend in mean arterial stiffness was also documented 
with increasing tertiles of different inflammatory 
biomarkers. Future studies are needed to investigate the 
discriminant value of arterial stiffness to predict major 
CVD events within various inflammatory disorders.
Cardiovascular diseases (CVD) represent a major 
burden among people diagnosed with chronic 
inflammatory disorders. For instance, several 
inflammatory disorders (eg, rheumatoid arthritis 
(RA), psoriasis and inflammatory bowel disorders 
(IBD)) were found to confer a 50% increased risk 
of major vascular events (eg, myocardial infarction 
(MI), stroke) compared with the general popu-
lation.1–3 In addition to traditional vascular risk 
factors (eg, hypertension, dyslipidaemia, obesity, 
smoking), inflammation has been documented as 
a major determinant of CVD risk across diverse 
inflammatory disorders.1 These findings emphasise 
the importance of identifying the pathways through 
which chronic inflammation may lead to early CVD 
pathogenesis. Studies with small (mainly hospi-
tal-based) samples point towards a potential associ-
ation between inflammation with arterial stiffness, 
an independent predictor of future CVD events.4–6 
Research in this area remains primarily explor-
atory, however, with studies employing diverse 
non-invasive measures of arterial stiffness (eg, 
pulse wave velocity (PWV), augmentation index, 
stiffness index (SI)) across different populations, 
making it difficult to draw robust overall conclu-
sions.7–9 The UK Biobank study includes several 
physiological and imaging techniques that may 
facilitate early identification of future risk of CVDs. 
For instance, the study includes an SI measure as 
a surrogate marker for subclinical atherosclerosis. 
While studies with small healthy populations indi-
cate moderate correlation between the SI and the 
PWV,10 no studies have evaluated the prognostic 
value of SI within diverse inflammatory disorders. 
Recently, the study added data on leucocytes count 
that have been used as markers of inflammation 
severity. It has been documented, for instance, that 
leucocytes release cytokines, triggering further 
macrophage recruitment and the proliferation of 
smooth muscle cells within the vascular wall.11 In 
addition, protease secretion leads to endothelial 
damage of the coronary vessels, exposing throm-
bogenic collagen and predisposing the vessels to 
thrombus formation. Phagocytes release myelop-
eroxidase, which generates reactive oxygen species 
that are involved in the generation and progression 
of atherosclerosis and that contribute to the devel-
opment of plaque instability in acute MI.11 Whether 
chronic inflammation is associated with a surrogate 
marker of arterial stiffness is not clearly established. 
The present study aimed to address this concern 
within a large community-based sample of adults 
aged 40–69 years. The study’s main hypothesis 
was that arterial stiffness would be more common 
among inflammatory disorders relative to people 
in the general population, and that this association 
would vary with disease severity.
MethOds
data
The data for the present study come from the UK 
Biobank, a large population-based prospective 
study developed to facilitate detailed investigations 
about the determinants of diseases at population 
level. The UK Biobank collects detailed data from 
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over 500 000 participants aged 40–69, including lifestyle, demo-
graphics, clinical diagnoses, treatment, lab tests (ie, biomarkers), 
imaging and genotype information.12 A more detailed descrip-
tion of the UK Biobank data is provided elsewhere.12
The present study was restricted to a subset of study partici-
pants (n=171 125) with measured arterial stiffness at baseline. 
Participants diagnosed with RA, systemic lupus erythematosus 
(SLE), Sjogren syndrome, psoriasis, ankylosing spondylitis (AS), 
systemic vasculitis or IBD represented the exposed group. Partic-
ipants free of these diagnoses represent the comparison group. 
Following Shen et al13 the study excluded participants with a 
history of CVDs (including coronary heart disease, stroke and 
peripheral arterial disease) or type II diabetes. Because arterial 
stiffness represents a blood pressure independent predictor of 
CVD events,14 patients with previous hypertension have been 
included in the analyses. This procedure allowed to account for 
the potential modulatory role of antihypertensive therapies on 
arterial stiffness.15 All participants provided written informed 
consent.
Arterial stiffness outcomes
A photoplethysmograph transducer was placed on the index 
finger of the participant’s dominant hand and used to calculate 
an arterial SI. The SI was assessed as the height of the partici-
pants divided by the time between the first (systolic) and second 
(diastolic) wave peaks, and was expressed in metres per second 
(m/s). SI is a clinical marker of larger artery stiffness and has 
been found to be moderately correlated with PWV—the gold 
standard measure of arterial stiffness.10 A higher SI is considered 
indicative of stiffer arteries.
exposures
The study’s main exposure was a global measure of chronic 
inflammatory disorders, including RA, psoriasis, IBD, SLE, 
Sjogren syndrome, systemic vasculitis and AS. These measures 
were developed from participants’ self-reports and were recorded 
according to the International Classification of Diseases, 10th 
Revision criteria. To explore potential variation within specific 
inflammatory disorders, separate binary variables (yes/no) were 
developed for the most common inflammatory disorders, specif-
ically RA, IBD and psoriasis. Leucocytes count was used to cate-
gorise participants into tertiles of inflammation disease severity. 
A composite granulocytes count-based inflammation severity 
measure was also developed. This measure classified participants 
into tertiles based on the average count of neutrophil, basophil 
and eosinophil biomarkers. An inflammation duration vari-
able, which classified participants into tertiles of disorder dura-
tion, was used for sensitivity analyses.
covariates
The study covariates included sociodemographic characteristics, 
specifically age (continuous measure), gender (female vs male), 
ethnicity (White, Black, Asian, Other) and deprivation. Depriva-
tion was based on Townsend deprivation indices derived from 
aggregated data on car ownership, household overcrowding, 
owner occupation and unemployment (higher scores repre-
sent higher degree of deprivation). The study also adjusted for 
traditional vascular risk factors, including smoking (never, ex, 
current smoker), hypertension (yes/no), hypercholesterolaemia 
(yes/no) and body mass index (BMI; kg/m2). Antihypertensive 
and lipid-lowering drugs (yes/no) were also included as covari-
ates. Non-steroidal anti-inflammatory drugs (NSAID) and corti-
costeroid drugs were included as separate binary covariates (they 
may have different impact on leucocytes count) due to their 
association with increased CVD risk.16 Sensitivity analyses also 
adjusted for disease-modifying antirheumatic drug (DMARD) 
prescribing.
statistical analysis
Descriptive analyses (eg, frequencies, means) were used to 
describe baseline characteristics among participants diagnosed 
with inflammatory disorders and the comparison group. The 
associations between inflammatory disorders with the SI were 
estimated using multivariable linear regression analyses with 
robust SE. Separate estimation models were performed for 
overall and specific inflammatory disorder (eg, RA, psoriasis 
and IBD). All models adjusted for age, sex, deprivation, BMI, 
smoking, ethnicity, previous diagnoses of hypertension and 
hypercholesterolaemia, anti-inflammatory drugs, as well as anti-
hypertensive and lipid-lowering medications. Analyses consid-
ering multiple imputation provided similar estimates to the main 
estimation models and only the latter are presented here. To test 
for potential dose–response associations, linear regression was 
used to compare inflammatory participants in different leuco-
cytes count tertiles to the reference group of no chronic inflam-
matory disorder.1 Sensitivity analyses stratified by inflammation 
disorder were also performed. Additional sensitivity analyses 
exploring the association between inflammatory disorder dura-
tion with the SI measure and adjusting for DMARDs were 
performed. The study did not adjust for multiple comparisons as 
it could increase the risk of type II errors.17 Results are reported 
as β estimates with 95% CIs. All analyses were conducted using 
STATA V.14 software (regress command with the robust option), 
using a P value of 0.05 as the threshold for statistical significance.
results
After excluding participants with a diagnosis of CVD or diabetes 
prior to SI assessment, the analyses included 5976 participants 
diagnosed with an inflammatory disorder and 165 149 partic-
ipants without an inflammatory disorder. The most common 
disorder was psoriasis (n=2019), followed by RA (n=1679) and 
IBD (n=1392). For all groups, the distribution of age was similar 
(table 1). Women were over-represented across all conditions, 
except psoriasis (48%). Participants diagnosed with chronic 
inflammatory disorders presented with higher prescribing rates 
of NSAIDs (25%), corticosteroids (14%), DMARDs (18%) and 
antihypertensive (21%) drugs relative to the comparison group 
(18%, 3%, 0% and 16%, respectively).
Figure 1 (see online supplementary figure S1 for data on all 
inflammatory disorders) illustrates the adjusted and unadjusted 
mean SI values for chronic inflammatory participants and their 
comparison group. Mean SI values were higher in the group 
(9.46, 95% CI 9.38 to 9.53) relative to the comparison group 
(9.32, 95% CI 9.31 to 9.34). Also, RA (9.47, 95% CI 9.33 to 
9.62), IBD (9.48, 95% CI 9.33 to 9.63) and psoriasis (9.49, 
95% CI 9.36 to 9.61) disorders presented with the highest mean 
values for the SI.
Multivariable linear regression analyses (table 2) revealed 
that chronic inflammatory disorders were associated with 
14% increase in mean arterial stiffness value (β=1.14, 95% CI 
1.05 to 1.25, P=0.002) compared with no chronic inflamma-
tory disorder. Mean SI values increased gradually with tertiles 
of the composite biomarkers of inflammation. For instance, 
the SI increased from 11% in the first tertile (95% CI 0.96 to 
1.29, P=0.162) to 17% in the second tertile (95% CI 1.02 to 
1.34, P=0.029), and 21% in the third tertile (1.21, 95% CI 
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1.05 to 1.39, P=0.009) of leucocytes count. Postestimation 
analyses revealed that the differences in mean arterial stiffness 
between the three leucocyte tertiles were statistically significant 
(P value=0.031). A similar pattern emerged with regard to the 
composite granulocytes count measure; however, the association 
was statistically significant only at the highest tertile of granulo-
cytes count (1.23, 95% CI 1.06 to 1.42, P=0.005).
Mean SI was also increased within RA (1.18, 95% CI 1.01 
to 1.39, P=0.044) and psoriasis (1.21, 95% CI 1.03 to 1.32, 
P=0.016), but not IBD (1.14, 95% CI 0.98 to 1.35, P=0.091) 
disorders (table 3). A statistically significant association between 
severity of inflammation with mean SI was revealed within both 
RA and psoriasis disorders. In adjusted analyses, however, the 
association was statistically significant only at the highest tertile 
of granulocytes count for psoriasis (1.29, 95% CI 1.03 to 1.60, 
P<0.001).
sensitivity analyses
Analyses that stratified participants by inflammation disorder 
revealed a gradual increment in mean SI with higher tertiles 
of leucocytes count. The increase was statistically significant 
in the reference group but not in the chronic inflammation 
group, possibly due to insufficient power for the latter. SI values 
increased linearly from the first to the third tertile of inflamma-
tory disorder duration (years since diagnosis), being statistically 
table 1 Participants’ characteristics at baseline assessment
All (5976) rA (n=1672) Psoriasis (2091) Ibd (1392) unexposed (165 149)
Age, mean (SD) 58 (8) 59 (7) 57 (8) 57 (8) 57 (8)
Gender, female 3486 (58) 1173 (70) 1013 (48) 783 (56) 93 312 (55)
Deprivation, mean (SD) −1.17 (3) −1.06 (3) −1.10 (3) −1.31 (3) −1.21 (3)
Ethnicity
  White 5726 (94) 1534 (92) 1988 (95) 1320 (95) 150 412 (92)
  Asian 183 (3) 68 (4) 56 (3) 37 (3) 5368 (3)
  Black 76 (1) 31 (2) 8 (1) 11 (1) 4913 (3)
  Other 100 (2) 34 (2) 31 (1) 19 (1) 4024 (2)
Smoker
  Never 2921 (49) 827 (50) 979 (47) 683 (49) 93 508 (57)
  Ex 2344 (39) 654 (39) 805 (39) 586 (42) 54 919 (33)
  Current 686 (12) 183 (11) 298 (14) 120 (9) 15 813 (10)
BMI, mean (SD), kg/m2 27.65 (5) 27.72 (5) 28.11 (5) 26.98 (4) 27.24 (5)
Antihypertensive drugs 1292 (21) 390 (23) 414 (20) 257 (18) 27 127 (16)
Statins 748 (12) 238 (14) 254 (12) 142 (10) 17 619 (11)
NSAIDs 1535 (25) 600 (36) 451 (22) 211 (15) 29 636 (18)
Corticosteroids 866 (14) 266 (13) 166 (12) 108 (8) 4297 (3)
DMARDs 1125 (18) 694 (42) 168 (8) 162 (12) 301 (0)
Hypertension 1830 (30) 542 (32) 611 (29) 349 (25) 41 984 (25)
Hypercholesterolemia 809 (13) 229 (14) 305 (15) 136 (10) 20 726 (13)
Figures are numbers and percentages unless otherwise specified.
DMARD, disease-modifying antirheumatic drug; IBD, inflammatory bowel disorder; NSAID, non-steroidal anti-inflammatory drug; RA, rheumatoid arthritis. 
Figure 1 Unadjusted and adjusted mean values for the arterial stiffness index across the study groups. IBD, inflammatory bowel disorder.
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significant at the middle (1.16, 95% CI 1.01 to 1.34, P=0.038) 
and highest tertiles (1.18, 95% CI 1.03 to 1.35, P=0.019) of 
disorder duration (online supplementary table S1). A similar 
pattern was also apparent between the SI with RA and IBD 
disorder duration. Finally, adjusting for DMARD prescribing did 
not alter the direction or statistical significance of associations.
dIscussIOn
Using a large community sample, an overall measure of major 
chronic inflammatory disorders was associated with higher rates 
of arterial stiffness. The association appeared to increase with 
the severity of chronic inflammation, as assessed by a composite 
measure of inflammatory biomarkers (eg, leucocytes count 
and granulocytes count). Within each composite measure, for 
instance, the association with arterial stiffness increased gradu-
ally from the first to the third tertile. These findings support the 
possibility of a dose–response association between inflammation 
severity with a non-invasive measure of arterial stiffness.
Inflammatory disorder-specific analyses supported a modest 
association between arterial stiffness with psoriasis and RA 
disorders, but less so with regard to IBDs. This suggestion 
was supported by the evidence that the SI increased with each 
tertile of granulocytes count within the psoriasis disorder. No 
clear dose–response relationship was observed with regard to 
the leucocytes count measure, implying that leucocytes count 
may be an insensitive and non-specific marker of inflammation 
severity or that the study was insufficiently powered for disor-
der-specific analyses. The UK Biobank’s intention to incorporate 
biomarker data on C-reactive protein (CRP) and rheumatoid 
factor would offer the opportunity to compare the prognostic 
value of leucocytes count with these established markers of 
chronic inflammation.
While specific chronic inflammatory disorders may vary with 
regard to clinical presentation and underlying risk factors,18 they 
all have in common elevated levels of low-grade inflammation. 
These heterogeneous conditions also present similar rates of 
cardiovascular complications, including major CVD events and 
atherosclerosis. These associations may vary with inflammation 
severity, and the present study findings documented the poten-
tial value of using composite measures of markers of chronic 
inflammation for these purposes. The extent to which these find-
ings are translated to specific chronic inflammatory disorders 
remains to be determined, however.
A growing number of studies suggest that inflammation could 
be responsible for part of the excess cardiovascular risk observed 
in patients with chronic inflammatory diseases. Recently, it was 
reported that, compared with control subjects, carotid-fem-
oral PWV and augmentation index were significantly higher 
in patients with chronic inflammation, including inflammatory 
bowel diseases (IBD), RA, SLE and systemic sclerosis.19–21 More-
over, a significant relationship between aortic stiffness and left 
ventricular systolic and diastolic dysfunction was reported in 
table 2 Exponentiated coefficients and associated 95% CI for the association between overall chronic inflammatory disorders and inflammation 




P valueβ (95% cI) β (95% cI)
Overall inflammatory disorders 1.29 (1.19 to 1.40) 0.001 1.14 (1.05 to 1.24) 0.002
severity
Leucocytes count, range ×109 cells/L (minimum-maximum)
  First tertile (0.01–6.11) 1.08 (0.93 to 1.25) 0.294 1.11 (0.96 to 1.29) 0.162
  Second tertile (6.12–7.69) 1.32 (1.14 to 1.51) 0.001 1.17 (1.02 to 1.34) 0.029
  Third tertile (7.7–45.91) 1.57 (1.36 to 1.81) 0.001 1.21 (1.05 to 1.39) 0.009
Granulocytes count, range ×109 cells/L (minimum-maximum)
  First tertile (0.01–1.31) 1.06 (0.92 to 1.23) 0.414 1.12 (0.97 to 1.30) 0.114
  Second tertile (1.31–1.73) 1.26 (1.10 to 1.44) 0.001 1.13 (0.98 to 1.29) 0.084
  Third tertile (1.74–6.65) 1.61 (1.39 to 1.86) 0.000 1.23 (1.06 to 1.42) 0.005
β, exponentiated coefficient.
table 3 Exponentiated coefficients and associated 95% CIs for the association between specific chronic inflammatory disorders and inflammation 
severity with the arterial stiffness index













Disorder 1.29 (1.09 to 1.52) 1.18 (1.01 to 1.39) 1.39 (1.22 to 1.58) 1.17 (1.03 to 1.32) 1.15 (0.98 to 1.36) 1.15 (0.98 to 1.35)
severity
Leucocytes count tertiles
  First 1.19 (0.88 to 1.60) 1.20 (0.90 to 1.61) 1.03 (0.82 to 1.29) 1.02 (0.82 to 1.28) 1.08 (0.81 to 1.45) 1.17 (0.88 to 1.55)
  Second 1.24 (0.93 to 1.64) 1.16 (0.88 to 1.52) 1.66 (1.33 to 2.08) 1.36 (1.09 to 1.69) 1.24 (0.93 to 1.66) 1.24 (0.94 to 1.65)
  Third 1.59 (1.19 to 2.13) 1.25 (0.93 to 1.67) 1.65 (1.32 to 2.07) 1.21 (0.97 to 1.50) 1.18 (0.89 to 1.56) 1.10 (0.83 to 1.45)
Granulocytes count tertiles
  First 1.14 (0.85 to 1.52) 1.23 (0.91 to 1.67) 1.12 (0.89 to 1.42) 1.13 (0.90 to 1.42) 1.14 (0.85 to 1.53) 1.26 (0.94 to 1.69)
  Second 1.33 (1.00 to 1.75) 1.24 (0.93 to 1.65) 1.45 (1.16 to 1.81) 1.18 (0.95 to 1.47) 1.19 (0.90 to 1.58) 1.21 (0.92 to 1.59)
  Third 1.56 (1.16 to 2.11) 1.31 (0.96 to 1.80) 1.71 (1.37 to 2.15) 1.29 (1.03 to 1.60) 1.19 (0.89 to 1.59) 1.09 (0.82 to 1.45)
β, exponentiated coefficient.
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patients with IBD.22 This finding may explain the link between 
increased aortic stiffness with CVD events in patients with IBD 
and why these patients present with an increased CVD risk 
despite a low prevalence of classical cardiovascular risk factors.
Empirical evidence about differences in arterial stiff-
ness between diverse chronic inflammatory disorders and 
the general population is unavailable, precluding any direct 
comparison between this study findings with previous research. 
Nevertheless, the findings for increased arterial stiffness asso-
ciated with psoriasis and RA disorders are in line with earlier 
evidence with smaller samples and different surrogate markers 
of arterial stiffness.15 23 24 Booth et al25 found increased arterial 
stiffness among 31 patients diagnosed with systemic vasculitis, 
but the association was limited to patients (n=15) with active 
disease. The current study findings for a statistically significant 
association between arterial stiffness with the highest tertiles 
of leucocytes and granulocytes count point towards similar 
evidence across multiple chronic inflammatory disorders. The 
present study findings appear to support earlier evidence for a 
lack of association between arterial stiffness with IBDs,26 but 
this suggestion needs to be interpreted within the constraints 
of insufficient statistical power. Recent meta-analyses20 21 
reported increased augmentation index and carotid-femoral 
PWV among patients diagnosed with IBD. The higher, but 
not statistically significant, SI for IBD condition in this study 
may be explained by the use of a surrogate marker of arte-
rial stiffness or the remission of disease in participants diag-
nosed with IBD. These explanations may also account for the 
lack of association between white blood cells with the SI in 
this study, which is not in line with suggestions from a recent 
meta-analysis.22
strengths and limitations
The present study has several strengths, including large popu-
lation sample, comprehensive phenotype data, physiological 
measures of inflammatory biomarkers and objectively assessed 
arterial stiffness. As with most observational studies, several 
limitations need consideration in interpreting the study find-
ings. The UK Biobank data are based on self-reported chronic 
inflammatory disorders, which may increase the risk of 
misclassification bias. If inflammatory disorder diagnosis was 
over-reported or under-reported, this bias may slightly atten-
uate or strengthen the association with arterial stiffness. The 
prevalence of chronic inflammatory disorders in this study was 
similar to earlier investigations,1 suggesting minimal misclas-
sification bias. The estimation models were limited by the UK 
Biobank data available at time of study, and direct measures of 
disease activity (eg, disease activity score) or direct measures 
of arterial stiffness could not be considered. The present study 
analyses used composite measures of inflammatory biomarkers 
(eg, leucocytes, granulocytes), as surrogate markers of inflam-
mation severity. These biomarkers have been documented in 
the past to differentiate between the preclinical and clinical 
phases on CVDs.27 Plans to include CRP and rheumatoid 
factor measures into the UK Biobank data would provide for 
future validation studies with more direct biomarker measure-
ments. As with any observational data, the health survivor bias 
is a possibility within the UK Biobank. This limitation is of 
a greater concern for generalising the findings about disease 
prevalence, and less so about generalising the effect size 
estimates.28 The SI, as assessed by the PulseTrace technique, 
was found to be only moderately correlated with PWV.29 
The statistically significant associations and the documented 
dose–response relationship appear to support a potential 
role of the SI in the context of inflammatory disorders. This 
suggestion needs confirmation with future prospective studies, 
however. Notably, the moderate correlation between SI with 
PWV observed in Salvi et al’s study29 could be due to the study 
insufficient statistical power (n=50) or limited generalisability 
(just one participant presented a diagnosis of an inflammatory 
disorder). Information on left ventricular dysfunction, known 
to be associated with inflammation and CVD risk,30 was not 
available in the data. The linkage of the UK Biobank data 
with patients’ medical records in the near future would allow 
for more detailed investigations, including the association 
between increased arterial stiffness and CVD events in patients 
diagnosed with chronic inflammation. It would also provide 
for other investigations, including the impact of anti-tumour 
necrosis factor therapy on the arterial SI and for validating the 
diagnosis of chronic inflammatory disorders. The study data 
were underpowered to provide robust estimates on the asso-
ciation between arterial stiffness with other specific CIs (eg, 
SLE, AS, systemic vasculitis). Preliminary analyses appeared 
supportive of increased arterial stiffness within AS and vascu-
litis disorders, but these findings need validation with larger 
samples.
cOnclusIOns
Overall, this study findings support a potential association 
between markers of chronic inflammation with an estimate of 
arterial stiffness. The study findings also document a poten-
tial role of composite measures of inflammatory biomarkers 
to discriminate among people diagnosed with inflamma-
tory disorders at different risk of future CVDs. Whether the 
addition of composite measures of inflammatory biomarkers 
to traditional CVD risk scores (eg, QRISK2, Framingham) 
improves the latter discriminant and predictive values within 
chronic inflammatory disorders awaits further confirmation 
from prospective studies. Plans to include an MRI-based 
measure of PWV on the full UK Biobank sample would offer 
the opportunity to further validate the accuracy of the SI as 
an estimate of arterial stiffness within the context of chronic 
inflammatory disorders.
Key messages
What is already known on this subject?
Patients diagnosed with chronic inflammatory disorders are 
at increased risk of major cardiovascular events. Strategies to 
facilitate early identification of subclinical atherosclerosis in 
chronic inflammation have been proposed over the past years.
What might this study add?
Arterial stiffness index was increased among participants 
diagnosed with chronic inflammatory, including rheumatoid 
arthritis and psoriasis. The association varied with the 
distribution of inflammatory biomarkers as markers of 
inflammation severity.
how might this impact on clinical practice?
The stiffness index, a non-invasive measure of arterial stiffness, 
may provide additional prognostic and discriminatory value for 
future cardiovascular disease risk prediction within overall and 
specific chronic inflammatory disorders.
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